Every Form 4 that Sotera Health Company (SHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SHC filings page.
Sotera Health Co (SHC) reported that Executive Chairman Michael B. Petras Jr. sold shares of common stock on August 17, 2026. He sold 294,515 shares held directly and 850,000 shares held indirectly through a grantor trust at an average weighted price of $18.5011 per share, with trade prices ranging from $18.50 to $18.855. Following these transactions, he holds 397,912 shares directly and 3,969,393 shares indirectly through the grantor trust.
Sotera Health Co officer Michael P. Rutz, President of Sterigenics, reported a sale of 150,000 shares of common stock on 2026-08-07 in an open-market or private transaction. The sale was executed at a weighted-average price of $18.835 per share, with individual trades between $18.75 and $18.9050. Following this transaction, Rutz reports 334,279 shares of Sotera Health common stock held directly.
Sotera Health Co Sr. Vice President and CFO Jonathan M. Lyons reported a code F disposition in which 11,316 shares of common stock were withheld at $17.98 per share on August 5, 2026 to satisfy his tax withholding obligations upon vesting of 25,657 RSUs granted August 7, 2023 under the 2020 Incentive Plan.
Following this tax-withholding transaction, Lyons directly holds 217,304 common shares, plus unexercised stock options covering 81,676 shares at $14.59 and 33,640 shares at $16.89, and performance-based RSUs covering 11,958 and 29,678 shares, all granted under the Sotera Health Company 2020 Omnibus Incentive Plan with time- and performance-based vesting schedules.
Klee Ann R. reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Ann R. Klee received an equity award in the form of restricted stock units. On May 22, 2026, she was granted 14,970 RSUs under the Sotera Health Company 2020 Omnibus Incentive Plan, with no cash paid per unit.
Each RSU represents the right to receive one share of common stock, subject to vesting. The RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, provided she continues to serve as a non-employee director. After this grant, her reported holdings total 140,926 units and shares, consisting of 14,970 RSUs and 125,956 shares of common stock.
SHADER ALTON reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co reported that Chief Executive Officer Alton Shader received equity awards on May 26, 2026. He was granted 203,634 shares of Common Stock as RSUs and another 375,939 RSUs, all at no cash cost, plus 101,817 performance-based share appreciation units tied to Sotera’s stock price. The RSUs and SAUs generally vest in three equal annual installments starting March 2, 2027. After these grants, he directly holds 579,573 Common shares and 101,817 SAUs.
Kyle Richard G reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co reported that director Kyle Richard G received an equity grant in the form of restricted stock units. On May 22, 2026, he was awarded 14,970 RSUs, each representing the right to receive one share of common stock if vesting conditions are met.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or immediately before Sotera Health’s next regular annual shareholders meeting, provided he continues serving as a non-employee director through that date. Following this grant, he holds 14,970 shares/RSUs directly.
Krause Kenneth D. reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Kenneth D. Krause received a grant of 14,970 restricted stock units (RSUs) on May 22, 2026 as equity compensation. Each RSU represents the right to receive one share of common stock, subject to vesting conditions. The RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before Sotera Health’s next regular annual shareholders meeting, as long as Krause continues serving as a non-employee director. The Form 4 shows this as a non-cash award, with 14,970 shares reported as directly owned following the transaction.
CUNNINGHAM SEAN LAURENCE reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Sean Laurence Cunningham received an equity award as part of his board compensation. On May 22, 2026, he was granted 14,970 restricted stock units (RSUs), each representing the right to receive one share of common stock, for no cash payment.
The RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before Sotera Health’s next regular annual shareholders meeting, as long as he continues serving as a non-employee director. After this grant, Cunningham’s reported holdings total 95,751 units and shares, consisting of 14,970 RSUs and 80,781 shares of common stock.
Flynn Karen reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Karen Flynn reported receiving an equity award. She was granted 14,970 restricted stock units (RSUs) on May 22, 2026 under the Sotera Health Company 2020 Omnibus Incentive Plan. After this grant, she holds a total of 54,191 equity interests, consisting of 14,970 RSUs and 39,221 shares of common stock. The RSUs vest fully on the earlier of the first anniversary of the grant date or immediately before the company’s next regular annual shareholders meeting, assuming she continues serving as a non-employee director.
Neary James reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director James Neary received a grant of 14,970 restricted stock units (RSUs) of Common Stock. Each RSU equals one share, vesting in full on the earlier of the first anniversary of the grant or just before the next regular annual shareholders meeting, subject to his continued service as a non-employee director. Following this award, his holdings consist of 14,970 RSUs and 80,961 shares of Common Stock, totaling 95,751 share-equivalent interests.
PETRELLA VINCENT K reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Vincent K. Petrella received an equity grant of 14,970 restricted stock units (RSUs) of Common Stock on May 22, 2026. The award was made at no cash cost under the Sotera Health Company 2020 Omnibus Incentive Plan as director compensation.
Each RSU represents the right to receive one share of Common Stock, vesting in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, subject to his continued service as a non-employee director. Following this grant, his position consists of 14,970 RSUs and 80,961 shares of Common Stock, for a total of 95,751 shares and RSUs.
Chen Ruoxi reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Ruoxi Chen received an equity grant of 14,970 Restricted Stock Units (RSUs) on May 22, 2026. The RSUs were granted at no cash cost as part of the Sotera Health Company 2020 Omnibus Incentive Plan and represent the right to receive an equal number of common shares, subject to vesting conditions.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, assuming Chen continues serving as a non-employee director. Following this award, Chen holds 95,751 securities in total, consisting of 14,970 RSUs and 80,961 shares of common stock.
Sotera Health Co director Christopher Simon received a grant of 14,970 restricted stock units (RSUs) of Common Stock on May 22, 2026 as compensation. Each RSU converts into one share of Common Stock if vesting conditions are met. The RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, assuming he continues to serve as a non-employee director. After this award, Simon holds 34,102 equity interests in total, consisting of 14,970 RSUs and 19,132 shares of Common Stock held directly.
Wheadon David E. reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director David E. Wheadon received an equity grant of 14,970 restricted stock units (RSUs). The RSUs were awarded at no cash cost under the Sotera Health Company 2020 Omnibus Incentive Plan, as part of his compensation for serving as a non-employee director.
Each RSU represents the right to receive one share of common stock, subject to vesting. The grant vests in full on the earlier of the first anniversary of the grant date or immediately before the company’s next regular annual shareholders meeting, if he remains a director. Following this grant, he holds 89,882 shares and RSUs in total, consisting of 14,970 RSUs and 74,912 shares of common stock.
Sotera Health Co disclosed that investment entities affiliated with Warburg Pincus sold 19,102,952 shares of Common Stock of Sotera Health in an underwritten public secondary offering on May 13, 2026 at $15.168 per share.
After this transaction, the reporting Warburg Pincus entities reported zero shares of Sotera Health common stock in this filing and describe themselves collectively as the Warburg Pincus Entities, which may hold pecuniary interests through a complex partnership structure.
Sotera Health Co large shareholder entities affiliated with Warburg Pincus reported a major disposition of Common Stock. On May 13, 2026, certain Warburg Pincus Entities sold 19,102,952 shares of Sotera Health common stock in an underwritten public secondary offering. The reported indirect holdings for this line item fell to 0 shares following the transaction, and the entities disclaim beneficial ownership beyond any pecuniary interest.
Sotera Health Co disclosed that investment funds affiliated with GTCR sold 12,735,301 shares of Common Stock in an underwritten public secondary offering at $15.168 per share. These shares were held indirectly through GTCR XI funds and related entities.
Following this transaction, the reporting GTCR entities report zero shares of Sotera Health Common Stock held. The GTCR entities are described as directors-by-deputization for Section 16 purposes, and individual members of the GTCR board of managers disclaim beneficial ownership except for any pecuniary interest.
Sotera Health Co reported an insider equity event for former SVP, General Counsel and Secretary Alexander Dimitrief. On March 31, 2026, 7,941 shares of common stock were withheld at $14.34 per share to cover his tax obligations when 17,135 Restricted Stock Units granted on March 4, 2024 vested under the company’s 2020 Omnibus Incentive Plan upon his retirement. Following this tax-withholding disposition, he directly holds 312,040 shares of Sotera Health common stock.
Sotera Health Co disclosed that investment funds affiliated with Warburg Pincus sold 15,000,000 shares of Sotera Health common stock on March 6, 2026 in an underwritten public secondary offering at $15.27 per share. After this transaction, the Warburg Pincus entities continue to indirectly hold a total of 19,102,952 shares through Bull Holdco L.P. and Bull Co-Invest L.P.
Warburg Pincus–affiliated entities reported a major share sale in Sotera Health Co. On March 6, 2026, certain Warburg Pincus Entities sold 15,000,000 shares of Sotera Health common stock in an underwritten public secondary offering at $15.27 per share. After this transaction, Warburg Pincus–affiliated vehicles reported indirect holdings of 19,102,952 shares, consisting of 15,287,717 shares held by Bull Holdco L.P. and 3,815,235 shares held by Bull Co-Invest L.P. Each Warburg Pincus entity disclaims beneficial ownership beyond its pecuniary interest.
GTCR-affiliated funds associated with Sotera Health Co completed a large insider sale of Common Stock. On March 6, 2026, the GTCR XI Funds sold 10,000,000 shares of Sotera Health Common Stock in an underwritten public secondary offering at $15.27 per share.
After this transaction, the GTCR XI Funds collectively hold 12,735,301 shares, including 10,107,727 shares held by GTCR Fund XI/A LP, 2,546,564 shares held by GTCR Fund XI/C LP, and 81,010 shares held by GTCR Co-Invest XI LP. These holdings reflect a continued, but reduced, indirect ownership stake by the GTCR entities.
Sotera Health Co Chairman & CEO Michael B. Petras Jr. reported multiple equity compensation transactions dated March 2, 2026. He exercised 89,686 performance-based share appreciation units (SAUs) granted in 2025 into the same number of common shares and received new awards of 240,248 restricted stock units (RSUs) and 120,124 SAUs under the 2020 Incentive Plan. Several blocks of common stock were withheld at $15.91 per share to cover tax liabilities upon vesting of earlier RSU and SAU awards, rather than sold in the open market. Following these transactions, he directly owned 692,427 common shares and indirectly held 4,819,393 shares through a grantor trust.
Sotera Health Co SVP, General Counsel and Secretary Alexander Dimitrief reported equity award activity tied to restricted stock units and performance-based RSUs. On March 2, 2026, 16,816 performance-based RSUs converted into the same number of common shares following achievement of performance conditions, and related RSU grants from 2024 and 2025 partially vested.
To cover tax withholding obligations on these vestings, the issuer withheld 7,941 and 23,619 shares of common stock at a price of $15.91 per share, reported as tax-withholding dispositions rather than open-market sales. After these transactions, Dimitrief directly held 319,981 shares of common stock and 11,210 performance RSUs, with remaining additional RSUs scheduled to vest in March 2027 and March 2028, subject to performance conditions.
Sotera Health Co Senior Vice President and CFO Jonathan M. Lyons reported multiple equity-related transactions on March 2, 2026. Performance-based RSUs vested and were exercised into Common Stock, and he also received new RSU and performance-based RSU awards under the 2020 Omnibus Incentive Plan.
To cover tax withholding obligations from these vestings, the company withheld shares of Common Stock at $15.91 per share. After these awards, exercises, and tax-withholding dispositions, Lyons continued to hold a substantial number of Sotera Health common shares directly.
Sotera Health Co President of Sterigenics Michael P. Rutz reported multiple equity compensation transactions involving performance-based RSUs and common stock. On March 2, 2026, 14,573 performance RSUs were exercised into the same number of common shares, and 22,612 new performance RSUs were granted at no cash cost.
On the same date, he received a grant of 45,223 shares of common stock, and several blocks of common shares (3,729, 4,495, and 17,497 shares at $15.9100 per share) were disposed of to cover tax withholding tied to vesting RSU awards. Following these transactions, he directly held 484,279 shares of common stock and 22,612 performance RSUs, with additional RSUs and performance-based RSUs subject to future vesting and performance conditions under the 2020 Omnibus Incentive Plan.
Sotera Health Co director files insider report. Director Kyle Richard G submitted a Form 4 related to Sotera Health Co, indicating an earliest transaction date of 02/04/2026. The excerpted tables for non-derivative and derivative securities do not show specific transaction amounts or prices.
Sotera Health Company’s major shareholder group affiliated with Warburg Pincus reported a large insider sale of common stock. On December 3, 2025, certain Warburg Pincus entities sold 9,720,000 shares of Sotera Health common stock in a transaction executed under Rule 144 at a price of $16.33 per share.
After this sale, the reporting entities still beneficially own 34,102,952 shares of Sotera Health, held indirectly through Bull Holdco L.P. with 27,291,923 shares and Bull Co-Invest L.P. with 6,811,029 shares. The various Warburg Pincus funds and affiliates report their interest as directors-by-deputization for Section 16 purposes and each disclaims beneficial ownership beyond its economic interest.
Sotera Health Company’s major shareholder group, the GTCR XI Funds, reported a large stock sale. On December 3, 2025, these funds sold 6,480,000 shares of Sotera Health common stock at a price of $16.33 per share. The transaction was reported on a joint Form 4 filing by multiple GTCR-related entities, which are listed as both directors by deputization and 10% owners.
After this sale, the GTCR XI Funds reported beneficial ownership of 22,735,301 shares in total. This consists of 18,044,507 shares held by GTCR Fund XI/A LP, 4,546,174 shares held by GTCR Fund XI/C LP, and 144,620 shares held by GTCR Co-Invest XI LP. The filing notes that GTCR’s management entities and their board of managers may be deemed to share beneficial ownership, while individual managers disclaim beneficial ownership except for their economic interests.
Sotera Health (SHC): Insider Form 4 reports large sponsor sale. On 11/10/2025, the GTCR XI Funds sold 12,000,000 shares of Sotera Health common stock in an underwritten public secondary offering at $15.651 per share (transaction code S). Following the sale, the reporting persons beneficially owned 29,215,301 shares indirectly. The filing identifies the reporters as both a Director and a 10% Owner.
The remaining indirect holdings comprise 23,187,541 shares held by GTCR Fund XI/A LP, 5,841,921 by GTCR Fund XI/C LP, and 185,839 by GTCR Co-Invest XI LP, as described in the footnotes. Governance and control details are provided for the GTCR entities and their board of managers.
Sotera Health (SHC): Insider Form 4 filing — Warburg Pincus entities reported the sale of 18,000,000 shares of Sotera Health common stock in an underwritten public secondary offering on November 10, 2025, at $15.651 per share.
The reporting persons are indicated as both Director and 10% Owner, and the filing notes the sale was conducted by affiliated Warburg Pincus entities. The transaction was disclosed as a secondary sale by existing holders, not an issuance by the company.
Sotera Health Co (SHC) insiders affiliated with Warburg Pincus reported a sale of 18,000,000 shares of common stock in an underwritten public secondary offering on November 10, 2025 at $15.651 per share.
After the reported transaction, the reporting group indicated 43,822,952 shares beneficially owned on an indirect basis, as referenced in the footnotes. The filing identifies the reporting persons as both Director and 10% Owner and notes that the report was filed by more than one reporting person.